#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE

Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024 Many failed trails - likely secondary to non validated outcomes. 3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2

"T and B cells playing tennis" In Sjogren's Syndrome! Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U

Isolated ⬆️ serum #IgG4 level: 💎💎💎 (Dr. Stone): ❓How high? >5x ULN ➡️PPV 75%‼️ ❓Typical organ(s) involved? ❓Another explanation? #eular2024 #rheumx @eular_org @RheumNow https://t.co/pm6wjvi2Vt

Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT

How to assess treatment in Sjogren's Syndrome #EULAR2024 @RheumNow 1) define the target population 2) standardize inclusion criteria 3) Restricting ESSDAI domain to 5 domains 4) Correct endpoint choice https://t.co/m7DvZdpuZa

#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U

Sjogrens Syndrome - bench to bedside session. #EULAR2024 @RheumNow Important to concentrate on non infiltrative patients. (to find different / early phenotypes?) https://t.co/ezFkX6CW8l

Real world data of safety profiles in SpA and Secukinumab- in all age groups #POS0199 #EULAR2024 @RheumNow https://t.co/q0FFP2SMLl

Very contradictory study in Axial SpA- no evidence of better drug retention or better treatment response compared to a later start of treatment. Data of early and very early disease. POs0204 #EULAR2024 @RheumNow https://t.co/6ci6xfyRmq

What happens when RA patients only on csDMARDs want to stop their meds? in BIO-FLARE, only half flared within 6mo of stopping all csDMARDs suddenly. They’ve got a clinical predictive model. Many milder patients ask, and could benefit! #EULAR2024 POS0068 John Isaacs @RheumNow https://t.co/B7ZjP5Pj70

#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn